Lexicon Pharmaceuticals, Inc. ( LXRX ) was a big mover last session, as its shares rose over 61% on the day. The upside was driven by positive top-line results from a phase 3 telotristat etiprate study in cancer patients with carcinoid syndrome. This also led to far more shares changing hands than in a normal session. Yesterday's rally breaks the recent trend for the company, as the stock is now trading above the volatile price range of $8.15 to $9.72 in the past one-month time frame.
Over the last 30 days, the company witnessed one negative estimate revision while the Zacks Consensus Estimate remained unchanged. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Lexicon Pharmaceuticals currently has a Zacks Rank #4 (Sell) while its Earnings ESP is positive.
A better-ranked biomedical stock is Actelion Ltd. ( ALIOF ) with a Zacks Rank #1 (Strong Buy).
Is LXRX going up? Or down? Predict to see what others think: Up or Down
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
LEXICON PHARMA (LXRX): Free Stock Analysis Report
ACTELION LTD (ALIOF): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
